axicabtagene ciloleucel
AssetAlso called KTE-C19, Yescarta
Engineered CAR T cells recognize CD19 and kill CD19-expressing B cells, including malignant cells.
- Stage
- Approved
- Modality
- Cell therapy
- Target
- CD19
- 8
- Indications
- 39
- Trials
- 1
- Developer
Approved by the FDA on Oct 18, 2017 (BLA125643). 2 approvals stand. FDA
Indications
8Diffuse large B-cell lymphoma
Approved, FDA
DLBCL Arising From Follicular Lymphoma
Approved, FDA
Follicular lymphoma
Approved, FDA
5 more
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials39
- Evidence for its targets2
- Competitors11
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.